Panbela Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.34
- Today's High:
- $1.4
- Open Price:
- $1.39
- 52W Low:
- $1.26
- 52W High:
- $1197.1198
- Prev. Close:
- $1.35
- Volume:
- 19923
Company Statistics
- Market Cap.:
- $3.99 million
- Book Value:
- 1.838
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -93.6%
- Return on Equity TTM:
- -798.16%
Company Profile
Panbela Therapeutics Inc had its IPO on 2017-01-03 under the ticker symbol PBLA.
The company operates in the Healthcare sector and Biotechnology industry. Panbela Therapeutics Inc has a staff strength of 6 employees.
Stock update
Shares of Panbela Therapeutics Inc opened at $1.39 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.34 - $1.4, and closed at $1.4.
This is a +3.7% increase from the previous day's closing price.
A total volume of 19,923 shares were traded at the close of the day’s session.
In the last one week, shares of Panbela Therapeutics Inc have slipped by -3.45%.
Panbela Therapeutics Inc's Key Ratios
Panbela Therapeutics Inc has a market cap of $3.99 million, indicating a price to book ratio of 3.2198 and a price to sales ratio of 0.
In the last 12-months Panbela Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Panbela Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Panbela Therapeutics Inc’s operating margin was 0% while its return on assets stood at -93.6% with a return of equity of -798.16%.
In Q2, Panbela Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Panbela Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0.0076
- PEG
- 0
Its diluted EPS in the last 12-months stands at $178.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Panbela Therapeutics Inc’s profitability.
Panbela Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.2698. Its price to sales ratio in the trailing 12-months stood at 0.
Panbela Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $19.55 million
- Total Liabilities
- $10.56 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Panbela Therapeutics Inc ended 2024 with $19.55 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.55 million while shareholder equity stood at $4.80 million.
Panbela Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.56 million in other current liabilities, 3000.00 in common stock, $-102046000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.21 million and cash and short-term investments were $7.21 million. The company’s total short-term debt was $1,000,000 while long-term debt stood at $4.19 million.
Panbela Therapeutics Inc’s total current assets stands at $10.81 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $193000.00 compared to accounts payable of $8.44 million and inventory worth $0.
In 2024, Panbela Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Panbela Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.4
- 52-Week High
- $1197.1198
- 52-Week Low
- $1.26
- Analyst Target Price
- $23.5
Panbela Therapeutics Inc stock is currently trading at $1.4 per share. It touched a 52-week high of $1197.1198 and a 52-week low of $1197.1198. Analysts tracking the stock have a 12-month average target price of $23.5.
Its 50-day moving average was $1.77 and 200-day moving average was $34.34 The short ratio stood at 0.01 indicating a short percent outstanding of 0%.
Around 87% of the company’s stock are held by insiders while 442.8% are held by institutions.
Frequently Asked Questions About Panbela Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with cancer. The company’s lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101). The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.